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Perspective
Europe’s ‘Horizon 2020’ science funding
programme: how is it shaping up?
Michael Galsworthy1 and Martin McKee2
Abstract
Over the past 15 years, the European Union (EU) has spent around E80 billion on science research via Framework
Programmes (FP5, FP6 and FP7). In 2014, a new programme, Horizon 2020, will likely invest another E70 billion over 6
years. Health research has been a major part: between 12% and 17% was spent on official FP5 and FP6 health research
lines, although our work categorizing all EU science projects puts the health-related investment proportion nearer to
20%. Here, we compare our analyses and experiences with the European Commission’s own impact assessments and
plans that inform the Horizon 2020 programme. Much is moving in the right direction but some key gaps are overlooked.
We discuss four areas: red tape, what to fund, harnessing informatics and neglect of Eastern Europe.
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Finally an end to Eurocracy?
Bureaucracy has consequences. In 2004, Time magazine
attributed the nearly 400,000 European researchers in
the US to two key factors – funds and bureaucracy.1
Although many researchers were attracted by money
and opportunity, many more were escaping constraints
that faced them at home. The European Union (EU)
Framework Programmes (FPs) should have provided a
fresh opportunity, but their bureaucracy often sur-
passed the already cumbersome mechanisms present
in many European countries. In the early 2000s, even
ﬁnding project calls on the Commission’s research web-
site was extremely diﬃcult. Once calls ﬁnally started
appearing in a standard place, the associated documen-
tation purporting to help applicants often comprised
more pages than a PhD thesis.
The bureaucracy in European science funding has
been criticized so often that the message has ﬁnally
seeped through. In particular, concerns about the
adverse impact on smaller research institutes and small
and medium enterprises (SMEs) have been accepted.2
The Commission intends to reduce administration
costs by 15–20% in future. Submissions will be faster,
shorter and follow standardized practices. Additionally,
meaningless timesheets for those employed full-time
on EU projects will be abolished and reimbursement
of indirect costs will be simpliﬁed.2 These are
welcome steps.
Given the stated desire of Horizon 2020 is to foster
innovation and public–private partnerships, the
Commission could also simplify its sub-contracting
rules to encourage entrepreneurial dynamism.
Research increasingly requires innovative small and
medium enterprises to provide bespoke software and
hardware, an interaction which stimulates niche devel-
opments in European industry. Yet the tendering pro-
cess can be burdensome for all concerned. Many small
companies waste scarce time compiling bids which fail
and investigators are bound to strangers who present
the lowest bid regardless of passion or competence
beyond fulﬁlling minimal requirements.
For this reason, we recommend that sub-contracting
should not require compulsory tendering where the
sums fall below one of the European Commission
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(EC) procurement thresholds for public sector contract-
ing authorities (E130,000/E200,000). Of course, safe-
guards are needed but this could be covered by
governance arrangements already in place. These pro-
jects have been accepted, complete with budgetary
approval, so costing has already occurred. The selection
should now concern quality, which the project team are
best placed to judge. Projects should be encouraged to
advertise widely (an online virtual market place for rele-
vant businesses and projects would be a valuable
resource), but ultimately the projects should have
power to select and negotiate. The supposed risks asso-
ciated with trusting research teams to choose their busi-
ness partners are far outweighed by the speed,
eﬀectiveness, dynamism and opportunities gained by
unshackling companies and projects alike from this
costly bureaucratic burden.
So what was funded and why should
we care?
The US National Institutes of Health’s RePORTER
website has an online interface detailing the $30bn per
annum of research funded. It is possible to drill down
by geography, year or subject area to access what is
funded. The EC had no such well-developed interface
nor detailed subject area classiﬁcation for its FP5 and
FP6 projects. To analyse health-related research funded
by the EU, we had to manually classify over 4700
projects.3
There are clear beneﬁts to mapping scientiﬁc
research, particularly in the health domain where
research funding can be cross-referenced with measures
such as burden of disease or patient demand. Previous
research has indicated that in many health research
funding schemes, investment does not reﬂect societal
need.4 To the Commission’s credit, they have recog-
nized this and Horizon 2020 will address big societal
questions such as health and sustainability.2
Additionally, a detailed online hierarchical categoriza-
tion of EU investments allows national funders to see
collaboration opportunities or gaps, and it can shed
light on areas of research that might not withstand
wider scrutiny. We identiﬁed some E35 million spent
on antioxidants with many of the research abstracts
implying health beneﬁts. Sadly, after initial high-level
excitement (and despite continued marketing), it has
been known since the 1980s that supplemental antioxi-
dants are ineﬀective in cancer prevention and probably
dangerous. Finally, an online database of projects with
an analysis interface might resolve the E4 billion mis-
match we documented between what the EU had
claimed to spend under FP5 and FP6 (E34bn) and
what their oﬃcial databases showed (E30bn).3
Recommendations for integrating
innovation and science
Perhaps the most important recommendations we can
make relate to new trends in science informatics that
could increase productivity dramatically. The two key
issues are making projects fully digital object identiﬁer
(DOI) networked and open access to research
databases.
DOIs are unique codes for unambiguous online
identiﬁcation. The CrossRef collaboration of journals
has developed a DOI system to provide unique identi-
ties for scholarly articles which can then be linked elec-
tronically. Useful metadata can added to paper DOIs
(year, MeSH terms), or metrics calculated for groups of
paper DOIs (e.g. journal/author citation indices). An
obvious next step would be to create DOIs for individ-
ual researchers (analogous to the researcher IDs of the
Canadian Institute for Health Research), DOIs for
funded projects and DOIs for project databases.
Dealing ﬁrst with individual DOIs, rather than set-
ting up a new EU-only system the current eﬀort to
establish global researcher DOIs should be harnessed.
ORCID was launched in October 2012 (http://about.
orcid.org/), backed by an impressive list of academic
bodies ORCID provides researchers with a unique ID
and associates this ID with a regularly updated list of
publications (much like Thomson Reuters
ResearcherID – the code upon which ORCID is
based). The EU could mandate that all project appli-
cants sign up to ORCID. So long as ORCID provides
an appropriate application programming interface, the
EU could automatically send a list of researcher IDs to
ORCID at any time and obtain a list of up-to-date
publications for them. Similarly, to access outputs asso-
ciated with any project, project DOIs should be linked
to publication DOIs. Currently, anyone can enter a US
grant code in PubMed to retrieve that project’s output.
Further, this can be automated en masse via PubMed’s
application programming interface: eUtilities. If the
EU were to have unique grant codes and a contract
with PubMed to register those codes (as do other
major funders), the entire up-to-date list of publications
associated with any set of grant codes could be used to
populate a database almost instantly. This would cer-
tainly be superior to their recent painstaking exercise
that involved sending questionnaires to 12,000
researchers, then analysing 22% of those.5
Finally, the EC should mandate that all projects
funded should provide, as a deliverable, any databases
which they compile during the project. The case for
open data from publically funded research has been
advocated frequently3,6 to enable validation of results,
use in meta-analysis, novel unforeseen exploitation, and
mitigation of publication bias. The idea that raw data
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are a public good has led funding bodies in the UK,
such as the MRC and the Wellcome Trust, to advocate
for open data. However, a new gold standard would be
created should the EU mandate delivery of all data,
supply reviewers to check for third party usability,
then provide all databases in a central searchable
repository. There are already established database
archiving services such as FigShare and DataCite that
could cater for an EU account.
The unspoken Eastern European
underinvestment scandal
The EC’s Impact Assessment of Health Research
Projects published in November 2011 produced alarm-
ing ﬁndings. Participation rates (representation on pro-
jects) and the percentage of total EU research funding
each region receives varied markedly between member
states (Table 1). The original 15 member states had
received 34 times more health research funding under
FP7 than the 12 newest members. That diﬀerence
cannot be explained by the 3.8 times larger population
of the EU-15 members, nor their 13.3 times greater
combined GDP, nor even their 12.8 times greater con-
tribution to the EU budget. The diﬀerence represents
dramatic underfunding. Worse, both the participation
rate and the funding have dropped since FP6, and the
EU-12 gets less money per participation than the ‘rest
of the world’ group (which includes Africa, Asia, etc.),
despite contributing ﬁnancially to the common pool.
So who is to blame for this state of aﬀairs? It could
be that research infrastructure in these countries is
weak, evidence for which is their lack of participation
in major conferences.7 However, there is another poten-
tial factor. The net salary earned on an EU project in
Slovenia is only a third of what the same researcher
would receive in London. Each time project proposals
are written, all researchers must use local salaries, so
that the bulk of the budget moves to northwest Europe,
reﬂecting the higher salaries there. To believe the
diﬀerences reﬂect living costs ignores the ﬁnancial hard-
ship of Eastern European researchers. EU project
salary compensation oﬀers no respite, rather it rein-
forces the tilted playing ﬁeld and fuels the brain
drain. The participation to money ratios (Table 1) are
substantially explained by this salary diﬀerence.
Although in March 2012 the EU regional policy com-
missioner announced the need to prioritize the issue of
east to west brain drain,8 this issue is barely mentioned
in any of the Impact Assessments or proposals for
Horizon 2020.2,5
Our proposition is to pay researchers in New
Member States the same salary as in Western Europe.
Paying equitably would let Eastern Europe use its com-
petitive advantage of marginally lower living costs to
retain and even attract top researchers, so that
Principal Investigators can assimilate critical masses
of young eager talent. Additionally, it encourages
many more applications to EU projects and forces
local funders to match those compensation rates. This
is what EU science stimulation should be. And what is
the cost? Table 1 indicates that doubling all salaries to
Eastern European researchers would increase the
budget by only 2.5%.
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